Latest Ratios: P/E Ratio -0.4x · EV/EBITDA N/A · ROE -117.6%. (2012–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $4M | $17M | $41M | $73M | $92M | $196M | $74M | $28M | $18M | — | — |
| Enterprise Value | $1M | $14M | $32M | $49M | $65M | $186M | $74M | $28M | $13M | — | — |
| P/E Ratio → | -0.38 | — | — | — | — | 478.36 | — | — | — | — | — |
| P/S Ratio | 1.86 | 7.21 | 80.07 | 6.64 | 308.12 | 12.52 | 12.09 | 12.26 | 3.85 | — | — |
| P/B Ratio | 0.72 | 2.81 | 3.06 | 2.57 | 2.85 | 4.34 | 16.57 | 6.95 | 3.87 | — | — |
| P/FCF | — | — | — | — | — | 182.46 | — | — | — | — | — |
| P/OCF | — | — | — | — | — | 78.28 | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 5.90 | 62.93 | 4.50 | 218.68 | 11.91 | 12.10 | 12.19 | 2.74 | — | — |
| EV / EBITDA | — | — | — | — | — | 222.24 | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | 679.70 | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | 173.57 | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 26.3% | 26.3% | -417.1% | 71.8% | -393.6% | 87.2% | 43.7% | 18.9% | 65.0% | 32.8% | -196.3% |
| Operating Margin | -484.3% | -484.3% | -3349.7% | -68.5% | -5718.1% | 0.4% | -91.2% | -329.2% | -84.9% | -1244.2% | -9433.2% |
| Net Profit Margin | -484.6% | -484.6% | -3225.0% | -64.0% | -5660.5% | 1.5% | -94.1% | -481.6% | -130.5% | -1209.6% | -9571.9% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -117.6% | -117.6% | -79.5% | -23.2% | -43.7% | 1.0% | -134.8% | -252.4% | -169.5% | -293.6% | -377.8% |
| ROA | -77.9% | -77.9% | -62.9% | -19.5% | -38.0% | 0.8% | -53.5% | -112.8% | -73.0% | -98.2% | -201.3% |
| ROIC | -226.2% | -226.2% | -273.5% | -108.7% | -62.4% | 0.2% | -99.4% | -337.5% | -1016.1% | -606.0% | -717.3% |
| ROCE | -96.3% | -96.3% | -74.0% | -22.9% | -41.3% | 0.2% | -75.9% | -108.2% | -60.4% | -138.3% | -319.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.47 | 0.47 | 0.23 | 0.11 | 0.09 | 0.08 | 0.76 | 0.89 | 0.01 | 1.39 | — |
| Debt / EBITDA | — | — | — | — | — | 4.31 | — | — | — | — | — |
| Net Debt / Equity | — | -0.51 | -0.66 | -0.83 | -0.83 | -0.21 | 0.01 | -0.04 | -1.11 | -0.57 | -0.74 |
| Net Debt / EBITDA | — | — | — | — | — | -11.38 | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | -8.89 | — | — | — | — | — |
| Interest Coverage | -765.53 | -765.53 | -976.00 | -700.90 | -496.79 | 7.41 | -168.82 | -151.93 | -239.35 | -53.95 | -456.28 |
Net cash position: cash ($6M) exceeds total debt ($3M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.53 | 2.53 | 4.44 | 8.62 | 10.20 | 14.96 | 1.68 | 1.46 | 3.19 | 4.56 | 1.19 |
| Quick Ratio | 2.31 | 2.31 | 4.29 | 8.40 | 9.74 | 14.60 | 1.30 | 1.20 | 2.83 | 4.42 | 1.11 |
| Cash Ratio | 2.23 | 2.23 | 4.01 | 8.20 | 9.55 | 14.37 | 0.98 | 1.10 | 2.38 | 3.62 | 0.56 |
| Asset Turnover | — | 0.22 | 0.03 | 0.32 | 0.01 | 0.31 | 0.57 | 0.22 | 0.53 | 0.06 | 0.02 |
| Inventory Turnover | 3.05 | 3.05 | 6.05 | 4.33 | 1.03 | 1.85 | 2.74 | 2.12 | 2.35 | 1.52 | 1.78 |
| Days Sales Outstanding | — | 0.15 | 413.19 | 13.09 | 10.99 | 6.30 | 49.36 | 12.44 | 39.33 | 77.59 | 4567.51 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | 0.2% | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | 0.5% | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $12M | $11M | $11M | $11M | $12M | $7M | $5M | $4M | $3M | $2M |
Critical liquidity and dilution
Based on recent financial data, CLGN trades at a price-to-sales ratio of 1.71, a multiple that appears to reflect market optimism regarding milestone-driven revenue spikes rather than the underlying stability of its core commercial product lines or consistent long-term earnings potential for the biotechnology firm.
The current valuation multiple suggests that investors are pricing the company as a high-beta call option on the success of its AbbVie partnership. Given the lack of positive earnings, traditional P/E metrics are non-informative, and the P/S ratio may be artificially compressed by the lumpy, non-recurring nature of milestone payments.
As reported in quarterly filings, CLGN's ROIC has remained deeply negative, recently reaching -74.8%, which indicates that the company is currently destroying shareholder value rather than compounding it through its proprietary rhCollagen platform and ongoing clinical development efforts in the regenerative medicine space.
The consistent decay in returns on invested capital suggests that the high fixed costs associated with tobacco-based collagen production are not yet being offset by sufficient commercial scale. Investors should monitor whether future milestone payments can bridge this gap or if the capital intensity will continue to suppress returns.
According to recent financial statements, the company's cash conversion cycle has been highly erratic, recently reaching 145 days, which highlights significant challenges in managing inventory and receivables for a specialized biotechnology firm that is still transitioning from research-focused activities to a commercial sales organization.
The high days-in-inventory and days-sales-outstanding metrics suggest that the company faces structural hurdles in converting its biological assets into cash. This inefficiency appears to exacerbate the existing liquidity strain, as capital remains tied up in the production cycle rather than supporting immediate operational needs.
Based on the provided quarterly data, the current ratio has declined from 8.62 in 2023Q4 to 2.27 in 2026Q1, signaling a rapid contraction in the company's ability to cover short-term obligations as it continues to burn through its remaining cash reserves to fund ongoing operations.
While a current ratio of 2.27 may appear adequate in isolation, the rapid downward trend warrants caution given the company's negative operating margins. The lack of consistent cash flow generation suggests that the company may soon face a critical need for external financing to maintain its current R&D trajectory.
Investors frequently misapply top-line revenue growth as a proxy for commercial success, yet as reported in recent filings, the 360% year-over-year growth is largely driven by non-recurring milestone payments that obscure the actual market adoption of the company's BioInk and Vergenix product lines.
Relying on headline revenue growth without adjusting for milestone-driven lumpiness can lead to an overestimation of the company's steady-state earning power. A more appropriate metric for this business model would be recurring product revenue, which would better reflect the underlying commercial viability of the rhCollagen platform.
Includes 30+ ratios · 14 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CLGN stock.
CollPlant Biotechnologies Ltd.'s current P/E ratio is -0.4x. This places it at the 50th percentile of its historical range.
CollPlant Biotechnologies Ltd.'s return on equity (ROE) is -117.6%. The historical average is -135.1%.
Based on historical data, CollPlant Biotechnologies Ltd. is trading at a P/E of -0.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
CollPlant Biotechnologies Ltd. has 26.3% gross margin and -484.3% operating margin.